nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—ABCB1—Lisinopril—dilated cardiomyopathy	0.111	0.532	CbGbCtD
Sirolimus—ABCB1—Spironolactone—dilated cardiomyopathy	0.0974	0.468	CbGbCtD
Sirolimus—Hydronephrosis—Furosemide—dilated cardiomyopathy	0.0154	0.038	CcSEcCtD
Sirolimus—Tetany—Furosemide—dilated cardiomyopathy	0.00907	0.0224	CcSEcCtD
Sirolimus—Uremia—Lisinopril—dilated cardiomyopathy	0.00878	0.0217	CcSEcCtD
Sirolimus—Blood cholesterol increased—Furosemide—dilated cardiomyopathy	0.00734	0.0181	CcSEcCtD
Sirolimus—Amenorrhoea—Spironolactone—dilated cardiomyopathy	0.00619	0.0153	CcSEcCtD
Sirolimus—Pyelonephritis—Lisinopril—dilated cardiomyopathy	0.00584	0.0144	CcSEcCtD
Sirolimus—Local reaction—Furosemide—dilated cardiomyopathy	0.00534	0.0132	CcSEcCtD
Sirolimus—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.00534	0.0132	CcSEcCtD
Sirolimus—Cramps of lower extremities—Spironolactone—dilated cardiomyopathy	0.00499	0.0123	CcSEcCtD
Sirolimus—Hypomagnesaemia—Furosemide—dilated cardiomyopathy	0.00465	0.0115	CcSEcCtD
Sirolimus—Blood triglycerides increased—Furosemide—dilated cardiomyopathy	0.00451	0.0111	CcSEcCtD
Sirolimus—Renal pain—Lisinopril—dilated cardiomyopathy	0.00422	0.0104	CcSEcCtD
Sirolimus—Thrombosis—Furosemide—dilated cardiomyopathy	0.00418	0.0103	CcSEcCtD
Sirolimus—Azotaemia—Lisinopril—dilated cardiomyopathy	0.00416	0.0103	CcSEcCtD
Sirolimus—Generalised oedema—Lisinopril—dilated cardiomyopathy	0.00373	0.0092	CcSEcCtD
Sirolimus—Glycosuria—Furosemide—dilated cardiomyopathy	0.00365	0.009	CcSEcCtD
Sirolimus—Pelvic pain—Lisinopril—dilated cardiomyopathy	0.00365	0.00899	CcSEcCtD
Sirolimus—Fluid overload—Lisinopril—dilated cardiomyopathy	0.00357	0.0088	CcSEcCtD
Sirolimus—Gastritis—Spironolactone—dilated cardiomyopathy	0.00349	0.00861	CcSEcCtD
Sirolimus—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.00323	0.00797	CcSEcCtD
Sirolimus—Hyperuricaemia—Furosemide—dilated cardiomyopathy	0.00319	0.00786	CcSEcCtD
Sirolimus—Gout—Furosemide—dilated cardiomyopathy	0.00317	0.00781	CcSEcCtD
Sirolimus—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00314	0.00774	CcSEcCtD
Sirolimus—Hyperlipidaemia—Lisinopril—dilated cardiomyopathy	0.00308	0.00759	CcSEcCtD
Sirolimus—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.00301	0.00743	CcSEcCtD
Sirolimus—Haemoptysis—Lisinopril—dilated cardiomyopathy	0.003	0.00739	CcSEcCtD
Sirolimus—Herpes zoster—Lisinopril—dilated cardiomyopathy	0.00295	0.00727	CcSEcCtD
Sirolimus—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.0029	0.00714	CcSEcCtD
Sirolimus—Otitis media—Lisinopril—dilated cardiomyopathy	0.00285	0.00703	CcSEcCtD
Sirolimus—Cramps of lower extremities—Furosemide—dilated cardiomyopathy	0.00272	0.0067	CcSEcCtD
Sirolimus—Bladder pain—Furosemide—dilated cardiomyopathy	0.00267	0.00659	CcSEcCtD
Sirolimus—Urine output increased—Furosemide—dilated cardiomyopathy	0.00267	0.00659	CcSEcCtD
Sirolimus—Proteinuria—Lisinopril—dilated cardiomyopathy	0.00252	0.00623	CcSEcCtD
Sirolimus—Accidental injury—Lisinopril—dilated cardiomyopathy	0.00251	0.00618	CcSEcCtD
Sirolimus—Protein urine present—Lisinopril—dilated cardiomyopathy	0.00249	0.00614	CcSEcCtD
Sirolimus—Thrombophlebitis—Furosemide—dilated cardiomyopathy	0.00248	0.00611	CcSEcCtD
Sirolimus—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00247	0.00609	CcSEcCtD
Sirolimus—Viral infection—Lisinopril—dilated cardiomyopathy	0.00246	0.00606	CcSEcCtD
Sirolimus—Polyuria—Furosemide—dilated cardiomyopathy	0.00244	0.00603	CcSEcCtD
Sirolimus—Arthropathy—Lisinopril—dilated cardiomyopathy	0.00244	0.00602	CcSEcCtD
Sirolimus—Cough increased—Lisinopril—dilated cardiomyopathy	0.00242	0.00598	CcSEcCtD
Sirolimus—Oliguria—Lisinopril—dilated cardiomyopathy	0.00241	0.00594	CcSEcCtD
Sirolimus—Deafness—Furosemide—dilated cardiomyopathy	0.0024	0.00592	CcSEcCtD
Sirolimus—Gout—Lisinopril—dilated cardiomyopathy	0.00238	0.00586	CcSEcCtD
Sirolimus—Leukocytosis—Lisinopril—dilated cardiomyopathy	0.00236	0.00582	CcSEcCtD
Sirolimus—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.00233	0.00575	CcSEcCtD
Sirolimus—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00228	0.00563	CcSEcCtD
Sirolimus—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.00227	0.00561	CcSEcCtD
Sirolimus—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00222	0.00547	CcSEcCtD
Sirolimus—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.00222	0.00547	CcSEcCtD
Sirolimus—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.0022	0.00544	CcSEcCtD
Sirolimus—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.00218	0.00538	CcSEcCtD
Sirolimus—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00216	0.00531	CcSEcCtD
Sirolimus—Malaise—Spironolactone—dilated cardiomyopathy	0.00214	0.00528	CcSEcCtD
Sirolimus—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00213	0.00524	CcSEcCtD
Sirolimus—Fluid retention—Lisinopril—dilated cardiomyopathy	0.00211	0.00519	CcSEcCtD
Sirolimus—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.00209	0.00517	CcSEcCtD
Sirolimus—Neuropathy—Lisinopril—dilated cardiomyopathy	0.00208	0.00514	CcSEcCtD
Sirolimus—Urinary retention—Furosemide—dilated cardiomyopathy	0.00204	0.00503	CcSEcCtD
Sirolimus—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00201	0.00496	CcSEcCtD
Sirolimus—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00201	0.00495	CcSEcCtD
Sirolimus—Discomfort—Spironolactone—dilated cardiomyopathy	0.002	0.00493	CcSEcCtD
Sirolimus—Dehydration—Furosemide—dilated cardiomyopathy	0.002	0.00492	CcSEcCtD
Sirolimus—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.00197	0.00487	CcSEcCtD
Sirolimus—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00196	0.00483	CcSEcCtD
Sirolimus—Confusional state—Spironolactone—dilated cardiomyopathy	0.00196	0.00482	CcSEcCtD
Sirolimus—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00195	0.00482	CcSEcCtD
Sirolimus—Hypertonia—Lisinopril—dilated cardiomyopathy	0.00194	0.0048	CcSEcCtD
Sirolimus—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00194	0.00478	CcSEcCtD
Sirolimus—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.0019	0.00468	CcSEcCtD
Sirolimus—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00187	0.00461	CcSEcCtD
Sirolimus—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00185	0.00457	CcSEcCtD
Sirolimus—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00182	0.00449	CcSEcCtD
Sirolimus—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00182	0.00448	CcSEcCtD
Sirolimus—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00179	0.00442	CcSEcCtD
Sirolimus—Injury—Lisinopril—dilated cardiomyopathy	0.00175	0.00432	CcSEcCtD
Sirolimus—Somnolence—Spironolactone—dilated cardiomyopathy	0.00172	0.00425	CcSEcCtD
Sirolimus—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00171	0.00423	CcSEcCtD
Sirolimus—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.0017	0.00419	CcSEcCtD
Sirolimus—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00169	0.00417	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00167	0.00413	CcSEcCtD
Sirolimus—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00167	0.00413	CcSEcCtD
Sirolimus—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.00166	0.0041	CcSEcCtD
Sirolimus—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00165	0.00407	CcSEcCtD
Sirolimus—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00162	0.00399	CcSEcCtD
Sirolimus—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00161	0.00397	CcSEcCtD
Sirolimus—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.0016	0.00394	CcSEcCtD
Sirolimus—Sweating—Furosemide—dilated cardiomyopathy	0.00159	0.00391	CcSEcCtD
Sirolimus—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00156	0.00386	CcSEcCtD
Sirolimus—Face oedema—Lisinopril—dilated cardiomyopathy	0.00155	0.00383	CcSEcCtD
Sirolimus—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00153	0.00378	CcSEcCtD
Sirolimus—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00151	0.00372	CcSEcCtD
Sirolimus—Dehydration—Lisinopril—dilated cardiomyopathy	0.0015	0.00369	CcSEcCtD
Sirolimus—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00147	0.00363	CcSEcCtD
Sirolimus—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00147	0.00362	CcSEcCtD
Sirolimus—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00146	0.00359	CcSEcCtD
Sirolimus—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00146	0.00359	CcSEcCtD
Sirolimus—Visual impairment—Furosemide—dilated cardiomyopathy	0.00143	0.00353	CcSEcCtD
Sirolimus—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00143	0.00352	CcSEcCtD
Sirolimus—Gastritis—Lisinopril—dilated cardiomyopathy	0.00143	0.00351	CcSEcCtD
Sirolimus—Influenza—Lisinopril—dilated cardiomyopathy	0.00139	0.00343	CcSEcCtD
Sirolimus—Asthma—Lisinopril—dilated cardiomyopathy	0.00139	0.00343	CcSEcCtD
Sirolimus—Tinnitus—Furosemide—dilated cardiomyopathy	0.00138	0.00341	CcSEcCtD
Sirolimus—Pruritus—Spironolactone—dilated cardiomyopathy	0.00137	0.00338	CcSEcCtD
Sirolimus—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00136	0.00337	CcSEcCtD
Sirolimus—Angiopathy—Furosemide—dilated cardiomyopathy	0.00135	0.00332	CcSEcCtD
Sirolimus—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00134	0.00331	CcSEcCtD
Sirolimus—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00134	0.0033	CcSEcCtD
Sirolimus—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00133	0.00327	CcSEcCtD
Sirolimus—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00132	0.00326	CcSEcCtD
Sirolimus—Dysuria—Lisinopril—dilated cardiomyopathy	0.0013	0.00321	CcSEcCtD
Sirolimus—Neutropenia—Lisinopril—dilated cardiomyopathy	0.0013	0.00321	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00129	0.00319	CcSEcCtD
Sirolimus—Malnutrition—Furosemide—dilated cardiomyopathy	0.00129	0.00319	CcSEcCtD
Sirolimus—Dizziness—Spironolactone—dilated cardiomyopathy	0.00128	0.00316	CcSEcCtD
Sirolimus—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00128	0.00316	CcSEcCtD
Sirolimus—Flatulence—Furosemide—dilated cardiomyopathy	0.00127	0.00314	CcSEcCtD
Sirolimus—Weight increased—Lisinopril—dilated cardiomyopathy	0.00127	0.00312	CcSEcCtD
Sirolimus—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00126	0.00311	CcSEcCtD
Sirolimus—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00126	0.0031	CcSEcCtD
Sirolimus—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00125	0.00308	CcSEcCtD
Sirolimus—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00124	0.00306	CcSEcCtD
Sirolimus—Vomiting—Spironolactone—dilated cardiomyopathy	0.00123	0.00304	CcSEcCtD
Sirolimus—Rash—Spironolactone—dilated cardiomyopathy	0.00122	0.00302	CcSEcCtD
Sirolimus—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00122	0.00301	CcSEcCtD
Sirolimus—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00122	0.003	CcSEcCtD
Sirolimus—Headache—Spironolactone—dilated cardiomyopathy	0.00121	0.003	CcSEcCtD
Sirolimus—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00121	0.00298	CcSEcCtD
Sirolimus—Anaemia—Furosemide—dilated cardiomyopathy	0.00119	0.00295	CcSEcCtD
Sirolimus—Sweating—Lisinopril—dilated cardiomyopathy	0.00119	0.00293	CcSEcCtD
Sirolimus—Agitation—Furosemide—dilated cardiomyopathy	0.00119	0.00293	CcSEcCtD
Sirolimus—Haematuria—Lisinopril—dilated cardiomyopathy	0.00118	0.00292	CcSEcCtD
Sirolimus—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00117	0.00289	CcSEcCtD
Sirolimus—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00117	0.00289	CcSEcCtD
Sirolimus—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00116	0.00287	CcSEcCtD
Sirolimus—Leukopenia—Furosemide—dilated cardiomyopathy	0.00116	0.00285	CcSEcCtD
Sirolimus—Nausea—Spironolactone—dilated cardiomyopathy	0.00115	0.00284	CcSEcCtD
Sirolimus—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00112	0.00275	CcSEcCtD
Sirolimus—Hallucination—Lisinopril—dilated cardiomyopathy	0.00111	0.00273	CcSEcCtD
Sirolimus—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00111	0.00273	CcSEcCtD
Sirolimus—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.0011	0.00271	CcSEcCtD
Sirolimus—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.0011	0.00271	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00109	0.0027	CcSEcCtD
Sirolimus—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00109	0.00269	CcSEcCtD
Sirolimus—Confusional state—Furosemide—dilated cardiomyopathy	0.00106	0.00262	CcSEcCtD
Sirolimus—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00105	0.0026	CcSEcCtD
Sirolimus—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00104	0.00256	CcSEcCtD
Sirolimus—Shock—Furosemide—dilated cardiomyopathy	0.00104	0.00256	CcSEcCtD
Sirolimus—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00103	0.00255	CcSEcCtD
Sirolimus—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00103	0.00255	CcSEcCtD
Sirolimus—Skin disorder—Furosemide—dilated cardiomyopathy	0.00102	0.00253	CcSEcCtD
Sirolimus—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00102	0.00252	CcSEcCtD
Sirolimus—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00101	0.00249	CcSEcCtD
Sirolimus—Anorexia—Furosemide—dilated cardiomyopathy	0.00101	0.00248	CcSEcCtD
Sirolimus—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.001	0.00248	CcSEcCtD
Sirolimus—Chills—Lisinopril—dilated cardiomyopathy	0.001	0.00247	CcSEcCtD
Sirolimus—Hypotension—Furosemide—dilated cardiomyopathy	0.000986	0.00243	CcSEcCtD
Sirolimus—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00097	0.00239	CcSEcCtD
Sirolimus—Flatulence—Lisinopril—dilated cardiomyopathy	0.000956	0.00236	CcSEcCtD
Sirolimus—Tension—Lisinopril—dilated cardiomyopathy	0.000952	0.00235	CcSEcCtD
Sirolimus—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000947	0.00234	CcSEcCtD
Sirolimus—Nervousness—Lisinopril—dilated cardiomyopathy	0.000942	0.00232	CcSEcCtD
Sirolimus—Back pain—Lisinopril—dilated cardiomyopathy	0.000938	0.00231	CcSEcCtD
Sirolimus—Somnolence—Furosemide—dilated cardiomyopathy	0.000938	0.00231	CcSEcCtD
Sirolimus—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000932	0.0023	CcSEcCtD
Sirolimus—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000917	0.00226	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000911	0.00225	CcSEcCtD
Sirolimus—Tremor—Lisinopril—dilated cardiomyopathy	0.000909	0.00224	CcSEcCtD
Sirolimus—Pain—Furosemide—dilated cardiomyopathy	0.000902	0.00222	CcSEcCtD
Sirolimus—Constipation—Furosemide—dilated cardiomyopathy	0.000902	0.00222	CcSEcCtD
Sirolimus—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.0009	0.00222	CcSEcCtD
Sirolimus—Anaemia—Lisinopril—dilated cardiomyopathy	0.000896	0.00221	CcSEcCtD
Sirolimus—Angioedema—Lisinopril—dilated cardiomyopathy	0.000886	0.00219	CcSEcCtD
Sirolimus—Malaise—Lisinopril—dilated cardiomyopathy	0.000875	0.00216	CcSEcCtD
Sirolimus—Syncope—Lisinopril—dilated cardiomyopathy	0.00087	0.00214	CcSEcCtD
Sirolimus—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000869	0.00214	CcSEcCtD
Sirolimus—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000868	0.00214	CcSEcCtD
Sirolimus—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000863	0.00213	CcSEcCtD
Sirolimus—Palpitations—Lisinopril—dilated cardiomyopathy	0.000857	0.00211	CcSEcCtD
Sirolimus—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000852	0.0021	CcSEcCtD
Sirolimus—Cough—Lisinopril—dilated cardiomyopathy	0.000846	0.00209	CcSEcCtD
Sirolimus—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000834	0.00206	CcSEcCtD
Sirolimus—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000834	0.00206	CcSEcCtD
Sirolimus—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000826	0.00204	CcSEcCtD
Sirolimus—Chest pain—Lisinopril—dilated cardiomyopathy	0.000826	0.00204	CcSEcCtD
Sirolimus—Myalgia—Lisinopril—dilated cardiomyopathy	0.000826	0.00204	CcSEcCtD
Sirolimus—Anxiety—Lisinopril—dilated cardiomyopathy	0.000823	0.00203	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00082	0.00202	CcSEcCtD
Sirolimus—Discomfort—Lisinopril—dilated cardiomyopathy	0.000816	0.00201	CcSEcCtD
Sirolimus—Confusional state—Lisinopril—dilated cardiomyopathy	0.000798	0.00197	CcSEcCtD
Sirolimus—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000792	0.00195	CcSEcCtD
Sirolimus—Oedema—Lisinopril—dilated cardiomyopathy	0.000792	0.00195	CcSEcCtD
Sirolimus—Infection—Lisinopril—dilated cardiomyopathy	0.000786	0.00194	CcSEcCtD
Sirolimus—Shock—Lisinopril—dilated cardiomyopathy	0.000779	0.00192	CcSEcCtD
Sirolimus—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000777	0.00192	CcSEcCtD
Sirolimus—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000775	0.00191	CcSEcCtD
Sirolimus—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000773	0.00191	CcSEcCtD
Sirolimus—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000769	0.0019	CcSEcCtD
Sirolimus—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000765	0.00189	CcSEcCtD
Sirolimus—Asthenia—Furosemide—dilated cardiomyopathy	0.000757	0.00187	CcSEcCtD
Sirolimus—Anorexia—Lisinopril—dilated cardiomyopathy	0.000754	0.00186	CcSEcCtD
Sirolimus—Pruritus—Furosemide—dilated cardiomyopathy	0.000746	0.00184	CcSEcCtD
Sirolimus—Hypotension—Lisinopril—dilated cardiomyopathy	0.00074	0.00182	CcSEcCtD
Sirolimus—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000722	0.00178	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000721	0.00178	CcSEcCtD
Sirolimus—Insomnia—Lisinopril—dilated cardiomyopathy	0.000716	0.00177	CcSEcCtD
Sirolimus—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000711	0.00175	CcSEcCtD
Sirolimus—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000706	0.00174	CcSEcCtD
Sirolimus—Somnolence—Lisinopril—dilated cardiomyopathy	0.000704	0.00174	CcSEcCtD
Sirolimus—Dizziness—Furosemide—dilated cardiomyopathy	0.000698	0.00172	CcSEcCtD
Sirolimus—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000697	0.00172	CcSEcCtD
Sirolimus—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000688	0.0017	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000683	0.00169	CcSEcCtD
Sirolimus—Constipation—Lisinopril—dilated cardiomyopathy	0.000677	0.00167	CcSEcCtD
Sirolimus—Pain—Lisinopril—dilated cardiomyopathy	0.000677	0.00167	CcSEcCtD
Sirolimus—Vomiting—Furosemide—dilated cardiomyopathy	0.000671	0.00165	CcSEcCtD
Sirolimus—Rash—Furosemide—dilated cardiomyopathy	0.000665	0.00164	CcSEcCtD
Sirolimus—Dermatitis—Furosemide—dilated cardiomyopathy	0.000665	0.00164	CcSEcCtD
Sirolimus—Headache—Furosemide—dilated cardiomyopathy	0.000661	0.00163	CcSEcCtD
Sirolimus—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000652	0.00161	CcSEcCtD
Sirolimus—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000647	0.0016	CcSEcCtD
Sirolimus—Nausea—Furosemide—dilated cardiomyopathy	0.000627	0.00155	CcSEcCtD
Sirolimus—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000626	0.00154	CcSEcCtD
Sirolimus—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000626	0.00154	CcSEcCtD
Sirolimus—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000583	0.00144	CcSEcCtD
Sirolimus—Asthenia—Lisinopril—dilated cardiomyopathy	0.000568	0.0014	CcSEcCtD
Sirolimus—Pruritus—Lisinopril—dilated cardiomyopathy	0.00056	0.00138	CcSEcCtD
Sirolimus—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000542	0.00134	CcSEcCtD
Sirolimus—Dizziness—Lisinopril—dilated cardiomyopathy	0.000523	0.00129	CcSEcCtD
Sirolimus—Vomiting—Lisinopril—dilated cardiomyopathy	0.000503	0.00124	CcSEcCtD
Sirolimus—Rash—Lisinopril—dilated cardiomyopathy	0.000499	0.00123	CcSEcCtD
Sirolimus—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000499	0.00123	CcSEcCtD
Sirolimus—Headache—Lisinopril—dilated cardiomyopathy	0.000496	0.00122	CcSEcCtD
Sirolimus—Nausea—Lisinopril—dilated cardiomyopathy	0.00047	0.00116	CcSEcCtD
Sirolimus—FGF2—Signaling by ERBB4—RAF1—dilated cardiomyopathy	0.000346	0.000895	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—RAF1—dilated cardiomyopathy	0.000345	0.000893	CbGpPWpGaD
Sirolimus—MTOR—ErbB1 downstream signaling—RAF1—dilated cardiomyopathy	0.000345	0.000893	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—RAC1—dilated cardiomyopathy	0.000343	0.000886	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—RAC1—dilated cardiomyopathy	0.000343	0.000886	CbGpPWpGaD
Sirolimus—MTOR—VEGFA-VEGFR2 Pathway—RAF1—dilated cardiomyopathy	0.00034	0.000879	CbGpPWpGaD
Sirolimus—FGF2—PI-3K cascade—EGFR—dilated cardiomyopathy	0.000337	0.000872	CbGpPWpGaD
Sirolimus—MTOR—Regulation of Telomerase—EGFR—dilated cardiomyopathy	0.000335	0.000866	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000335	0.000866	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—RAF1—dilated cardiomyopathy	0.00033	0.000854	CbGpPWpGaD
Sirolimus—FGF2—PI3K/AKT activation—EGFR—dilated cardiomyopathy	0.000329	0.000851	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—RAF1—dilated cardiomyopathy	0.000329	0.00085	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—RAF1—dilated cardiomyopathy	0.000327	0.000846	CbGpPWpGaD
Sirolimus—FGF2—GAB1 signalosome—EGFR—dilated cardiomyopathy	0.000326	0.000844	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—RAF1—dilated cardiomyopathy	0.000325	0.000842	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—RAF1—dilated cardiomyopathy	0.000321	0.00083	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	0.00032	0.000828	CbGpPWpGaD
Sirolimus—FGF2—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—dilated cardiomyopathy	0.000319	0.000825	CbGpPWpGaD
Sirolimus—MTOR—Signaling by Insulin receptor—RAF1—dilated cardiomyopathy	0.000319	0.000824	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—RAC1—dilated cardiomyopathy	0.000315	0.000814	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—RAF1—dilated cardiomyopathy	0.000306	0.000792	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—RAF1—dilated cardiomyopathy	0.000306	0.000792	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	0.000306	0.000792	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—RAF1—dilated cardiomyopathy	0.000303	0.000785	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—RAF1—dilated cardiomyopathy	0.000301	0.000778	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—RAF1—dilated cardiomyopathy	0.000299	0.000775	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000298	0.00077	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000288	0.000745	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	0.000287	0.000742	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—SOD2—dilated cardiomyopathy	0.000284	0.000735	CbGpPWpGaD
Sirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—dilated cardiomyopathy	0.000278	0.000718	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—RAF1—dilated cardiomyopathy	0.000273	0.000705	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	0.000271	0.000702	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—GPX1—dilated cardiomyopathy	0.000271	0.000701	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of proteins—AGT—dilated cardiomyopathy	0.000269	0.000697	CbGpPWpGaD
Sirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—dilated cardiomyopathy	0.000269	0.000697	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.000268	0.000693	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—NPPA—dilated cardiomyopathy	0.000261	0.000676	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—RAF1—dilated cardiomyopathy	0.000261	0.000675	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000261	0.000674	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—RAF1—dilated cardiomyopathy	0.000257	0.000664	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PSEN2—dilated cardiomyopathy	0.000253	0.000655	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—ITGB1—dilated cardiomyopathy	0.000253	0.000654	CbGpPWpGaD
Sirolimus—FGF2—Signaling by SCF-KIT—EGFR—dilated cardiomyopathy	0.000252	0.000652	CbGpPWpGaD
Sirolimus—MTOR—PI-3K cascade—EGFR—dilated cardiomyopathy	0.00025	0.000647	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000248	0.000642	CbGpPWpGaD
Sirolimus—MTOR—Insulin Signaling—RAF1—dilated cardiomyopathy	0.000246	0.000637	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—RAF1—dilated cardiomyopathy	0.000245	0.000634	CbGpPWpGaD
Sirolimus—MTOR—PI3K/AKT activation—EGFR—dilated cardiomyopathy	0.000244	0.000631	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—RAF1—dilated cardiomyopathy	0.000244	0.000631	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—RAF1—dilated cardiomyopathy	0.000244	0.000631	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000243	0.000629	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—RAF1—dilated cardiomyopathy	0.000243	0.000628	CbGpPWpGaD
Sirolimus—MTOR—GAB1 signalosome—EGFR—dilated cardiomyopathy	0.000242	0.000626	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000242	0.000625	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—RAF1—dilated cardiomyopathy	0.000242	0.000625	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling of activated FGFR—EGFR—dilated cardiomyopathy	0.000241	0.000623	CbGpPWpGaD
Sirolimus—FGF2—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	0.000241	0.000623	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB4—EGFR—dilated cardiomyopathy	0.000237	0.000614	CbGpPWpGaD
Sirolimus—MTOR—ErbB1 downstream signaling—EGFR—dilated cardiomyopathy	0.000237	0.000612	CbGpPWpGaD
Sirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—dilated cardiomyopathy	0.000237	0.000612	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—ITGB1—dilated cardiomyopathy	0.000234	0.000605	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—RAC1—dilated cardiomyopathy	0.000233	0.000604	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—TAZ—dilated cardiomyopathy	0.000229	0.000592	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—RAF1—dilated cardiomyopathy	0.000227	0.000588	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—RAF1—dilated cardiomyopathy	0.000227	0.000588	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	0.000227	0.000588	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—EGFR—dilated cardiomyopathy	0.000226	0.000586	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—EGFR—dilated cardiomyopathy	0.000225	0.000583	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—RAF1—dilated cardiomyopathy	0.000225	0.000583	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—EGFR—dilated cardiomyopathy	0.000224	0.00058	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ANKRD1—dilated cardiomyopathy	0.000223	0.000577	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—RAF1—dilated cardiomyopathy	0.000223	0.000577	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—EGFR—dilated cardiomyopathy	0.000223	0.000577	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—RAF1—dilated cardiomyopathy	0.000222	0.000575	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—EGFR—dilated cardiomyopathy	0.00022	0.000569	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—CD36—dilated cardiomyopathy	0.000216	0.000558	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000215	0.000555	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000215	0.000555	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—ITGB1—dilated cardiomyopathy	0.000214	0.000554	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	0.00021	0.000543	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—EGFR—dilated cardiomyopathy	0.00021	0.000543	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	0.00021	0.000543	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—TAZ—dilated cardiomyopathy	0.00021	0.000543	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—RAF1—dilated cardiomyopathy	0.000209	0.00054	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—EGFR—dilated cardiomyopathy	0.000208	0.000538	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—SDHA—dilated cardiomyopathy	0.000207	0.000535	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—EGFR—dilated cardiomyopathy	0.000206	0.000534	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—EGFR—dilated cardiomyopathy	0.000205	0.000531	CbGpPWpGaD
Sirolimus—SLC47A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000204	0.000528	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—RAC1—dilated cardiomyopathy	0.000203	0.000526	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	0.000201	0.000521	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000199	0.000516	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—CD36—dilated cardiomyopathy	0.000199	0.000516	CbGpPWpGaD
Sirolimus—FGF2—Disease—NPPA—dilated cardiomyopathy	0.000198	0.000512	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000198	0.000511	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—EGFR—dilated cardiomyopathy	0.000194	0.000503	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000193	0.0005	CbGpPWpGaD
Sirolimus—FGF2—Disease—PSEN2—dilated cardiomyopathy	0.000192	0.000496	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—CD36—dilated cardiomyopathy	0.00019	0.000492	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—SDHA—dilated cardiomyopathy	0.00019	0.000491	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000188	0.000487	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—RAC1—dilated cardiomyopathy	0.000188	0.000486	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—EGFR—dilated cardiomyopathy	0.000187	0.000483	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	0.000186	0.000481	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000185	0.000479	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—CD36—dilated cardiomyopathy	0.000183	0.000473	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00018	0.000466	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00018	0.000466	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—RAC1—dilated cardiomyopathy	0.000179	0.000464	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—EGFR—dilated cardiomyopathy	0.000179	0.000463	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000177	0.000459	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	0.000177	0.000458	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—EGFR—dilated cardiomyopathy	0.000176	0.000455	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—RAC1—dilated cardiomyopathy	0.000172	0.000446	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—EGFR—dilated cardiomyopathy	0.000168	0.000435	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000168	0.000433	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—dilated cardiomyopathy	0.000167	0.000433	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—EGFR—dilated cardiomyopathy	0.000167	0.000433	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—EGFR—dilated cardiomyopathy	0.000166	0.000431	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—EGFR—dilated cardiomyopathy	0.000166	0.000428	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000165	0.000427	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—dilated cardiomyopathy	0.000163	0.000422	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ANKRD1—dilated cardiomyopathy	0.000161	0.000417	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—ITGB1—dilated cardiomyopathy	0.000159	0.000411	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000157	0.000407	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000157	0.000407	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000157	0.000405	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	0.000156	0.000403	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—EGFR—dilated cardiomyopathy	0.000156	0.000403	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	0.000156	0.000403	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—RAF1—dilated cardiomyopathy	0.000155	0.0004	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—EGFR—dilated cardiomyopathy	0.000154	0.000399	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—EGFR—dilated cardiomyopathy	0.000153	0.000396	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—EGFR—dilated cardiomyopathy	0.000152	0.000394	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TAZ—dilated cardiomyopathy	0.000152	0.000392	CbGpPWpGaD
Sirolimus—MTOR—Disease—NPPA—dilated cardiomyopathy	0.000147	0.00038	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000147	0.00038	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000146	0.000379	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—EGFR—dilated cardiomyopathy	0.000144	0.000373	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—EGFR—dilated cardiomyopathy	0.000143	0.00037	CbGpPWpGaD
Sirolimus—MTOR—Disease—PSEN2—dilated cardiomyopathy	0.000142	0.000368	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000142	0.000367	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000142	0.000366	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—CD36—dilated cardiomyopathy	0.000141	0.000365	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000139	0.000359	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	0.000138	0.000357	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SDHA—dilated cardiomyopathy	0.000137	0.000355	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CD36—dilated cardiomyopathy	0.000136	0.000351	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—RAF1—dilated cardiomyopathy	0.000135	0.000348	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000135	0.000348	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000134	0.000348	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—RAC1—dilated cardiomyopathy	0.000133	0.000344	CbGpPWpGaD
Sirolimus—FGF2—Immune System—ITGB1—dilated cardiomyopathy	0.00013	0.000336	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—RAC1—dilated cardiomyopathy	0.000128	0.000331	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—RAC1—dilated cardiomyopathy	0.000127	0.000329	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000126	0.000326	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—RAF1—dilated cardiomyopathy	0.000125	0.000322	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000123	0.000318	CbGpPWpGaD
Sirolimus—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	0.000122	0.000315	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000122	0.000315	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000122	0.000314	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000121	0.000313	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000119	0.000309	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000119	0.000309	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—RAF1—dilated cardiomyopathy	0.000119	0.000308	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AGT—dilated cardiomyopathy	0.000116	0.0003	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000115	0.000297	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	0.000114	0.000296	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—RAF1—dilated cardiomyopathy	0.000114	0.000296	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000111	0.000287	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD36—dilated cardiomyopathy	0.000111	0.000287	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000111	0.000286	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000107	0.000278	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—EGFR—dilated cardiomyopathy	0.000106	0.000275	CbGpPWpGaD
Sirolimus—FGF2—Immune System—RAC1—dilated cardiomyopathy	0.000104	0.00027	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	0.000104	0.000268	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PSEN2—dilated cardiomyopathy	9.97e-05	0.000258	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.87e-05	0.000255	CbGpPWpGaD
Sirolimus—FGF2—Disease—RAC1—dilated cardiomyopathy	9.65e-05	0.00025	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ITGB1—dilated cardiomyopathy	9.65e-05	0.00025	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—EGFR—dilated cardiomyopathy	9.24e-05	0.000239	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	9.2e-05	0.000238	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AGTR1—dilated cardiomyopathy	9.17e-05	0.000237	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—RAC1—dilated cardiomyopathy	8.91e-05	0.000231	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AGTR2—dilated cardiomyopathy	8.85e-05	0.000229	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCL2—dilated cardiomyopathy	8.85e-05	0.000229	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—RAF1—dilated cardiomyopathy	8.83e-05	0.000228	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—TNF—dilated cardiomyopathy	8.8e-05	0.000228	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ADRB2—dilated cardiomyopathy	8.7e-05	0.000225	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—EGFR—dilated cardiomyopathy	8.55e-05	0.000221	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AGT—dilated cardiomyopathy	8.52e-05	0.00022	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—RAF1—dilated cardiomyopathy	8.48e-05	0.000219	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—RAF1—dilated cardiomyopathy	8.44e-05	0.000218	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCR3—dilated cardiomyopathy	8.23e-05	0.000213	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD36—dilated cardiomyopathy	8.23e-05	0.000213	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—EGFR—dilated cardiomyopathy	8.16e-05	0.000211	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—RAF1—dilated cardiomyopathy	8.06e-05	0.000208	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ADRB1—dilated cardiomyopathy	7.97e-05	0.000206	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—EGFR—dilated cardiomyopathy	7.83e-05	0.000203	CbGpPWpGaD
Sirolimus—MTOR—Immune System—RAC1—dilated cardiomyopathy	7.75e-05	0.000201	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	7.5e-05	0.000194	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	7.48e-05	0.000193	CbGpPWpGaD
Sirolimus—SLCO1B1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	7.3e-05	0.000189	CbGpPWpGaD
Sirolimus—MTOR—Disease—RAC1—dilated cardiomyopathy	7.16e-05	0.000185	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	7.05e-05	0.000182	CbGpPWpGaD
Sirolimus—FGF2—Immune System—RAF1—dilated cardiomyopathy	6.93e-05	0.000179	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AGTR1—dilated cardiomyopathy	6.81e-05	0.000176	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RAC1—dilated cardiomyopathy	6.76e-05	0.000175	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.46e-05	0.000167	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AGT—dilated cardiomyopathy	6.45e-05	0.000167	CbGpPWpGaD
Sirolimus—FGF2—Disease—RAF1—dilated cardiomyopathy	6.4e-05	0.000165	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	6.38e-05	0.000165	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	6.31e-05	0.000163	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EGFR—dilated cardiomyopathy	6.05e-05	0.000157	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	6.01e-05	0.000155	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—RAF1—dilated cardiomyopathy	5.91e-05	0.000153	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—EGFR—dilated cardiomyopathy	5.81e-05	0.00015	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EGFR—dilated cardiomyopathy	5.79e-05	0.00015	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—GPX1—dilated cardiomyopathy	5.62e-05	0.000145	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.55e-05	0.000144	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EGFR—dilated cardiomyopathy	5.53e-05	0.000143	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CD36—dilated cardiomyopathy	5.47e-05	0.000142	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—GPX1—dilated cardiomyopathy	5.16e-05	0.000133	CbGpPWpGaD
Sirolimus—MTOR—Immune System—RAF1—dilated cardiomyopathy	5.14e-05	0.000133	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CD36—dilated cardiomyopathy	5.02e-05	0.00013	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RAC1—dilated cardiomyopathy	5.01e-05	0.00013	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AGT—dilated cardiomyopathy	4.93e-05	0.000127	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AGT—dilated cardiomyopathy	4.79e-05	0.000124	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—dilated cardiomyopathy	4.75e-05	0.000123	CbGpPWpGaD
Sirolimus—MTOR—Disease—RAF1—dilated cardiomyopathy	4.75e-05	0.000123	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AGT—dilated cardiomyopathy	4.52e-05	0.000117	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RAF1—dilated cardiomyopathy	4.48e-05	0.000116	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—dilated cardiomyopathy	4.39e-05	0.000113	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—dilated cardiomyopathy	4.05e-05	0.000105	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	3.73e-05	9.64e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	3.65e-05	9.45e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	3.63e-05	9.39e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—dilated cardiomyopathy	3.53e-05	9.12e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RAF1—dilated cardiomyopathy	3.32e-05	8.6e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	3.27e-05	8.45e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—dilated cardiomyopathy	3.26e-05	8.42e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—dilated cardiomyopathy	3.07e-05	7.95e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	2.81e-05	7.28e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CD36—dilated cardiomyopathy	2.74e-05	7.09e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AGT—dilated cardiomyopathy	2.47e-05	6.38e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—dilated cardiomyopathy	2.28e-05	5.9e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	1.73e-05	4.48e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	1.69e-05	4.37e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	1.52e-05	3.93e-05	CbGpPWpGaD
